Predict your next investment

HEALTHCARE | Biotechnology

See what CB Insights has to offer

Stage

Acquired | Acquired

About Trianta Immunotherapies

Trianta Immunotherapies was founded in late 2013 to exploit the therapeutic and commercial potential of innovative T cell-focused therapies developed by the team of Prof. Dolores Schendel at the Helmholtz Zentrum Munchen, in collaboration with Prof. Thomas Blankenstein at the Max Delbruck Centre for Molecular Medicine Berlin-Buch. The company is working on three platforms for the personalized treatment of various tumour types and stages, each one focused on T cells: Dendritic cell vaccines, clinical stage: inducing the maturation of own, cancer-specific T cells and triggering both T cells and natural killer cells to attack the tumor; suited for the treatment of minimal residual disease; Adoptive T cell therapy, late preclinical stage: arming patient-derived T cells ex vivo with suitable T cell receptors that enable them to detect and efficiently kill cancer cells in vivo; suited for the treatment of advanced cancer; and T cell-specific antibodies, proof-of-technology: depleting unwanted T cells based on their unique T cell receptors; intended for the treatment of T cell-mediated diseases or in preparation of transplantations.

Trianta Immunotherapies Headquarter Location

Am Klopferspitz 19 a

Planegg-Martinsried, D-82152,

Germany

+49 (0)89 3187-1301

Latest Trianta Immunotherapies News

European Patent to Strengthen Medigene’s Dendritic Cell DC Vaccines Program

Mar 5, 2015

Biotechnology company, Medigene AG (MDG1, Frankfurt, Prime Standard) announces that the European Patent Office has granted European Patent No. 2004807 "Composition for the preparation of mature dendritic cells", relating to the manufacturing of mature dendritic cells co-developed by scientists of today's Medigene Immunotherapies. The patent will have a term until 2027 and is licensed exclusively to Medigene Immunotherapies (formerly Trianta Immunotherapies) by the Helmholtz Zentrum München. Prof. Dolores Schendel, CSO of Medigene AG, comments: "This new patent will substantially extend the protection for our innovative products. The patent protects our unique process to generate polarised dendritic cells, the cocktail used in the process and the derived polarised dendritic cells, which are being used in the ongoing academic clinical trials and will be used in our upcoming company-sponsored clinical study. " About Medigene's DC vaccines: The platform for the development of antigen-tailored DC vaccines is the most advanced platform of the three highly innovative and complementary immunotherapy platforms of Medigene Immunotherapies (formerly Trianta Immunotherapies). Currently the DC vaccines are being evaluated in two ongoing investigator-initiated trials in clinical phases II (prostate cancer) and I/II (AML, acute myeloid leukaemia). Medigene concentrates on the further development of DC vaccines in hematological malignancies and plans to initiate a further clinical study in AML shortly. Medigene's dendritic cell product platform allows the design of new generation dendritic cell vaccines. Dendritic cells can take up antigens efficiently, process them and present them on their surface in a form that can induce antigen-specific T cells to proliferate and mature. This way T cells can recognize and eliminate antigen-bearing tumour cells. Dendritic cells can also induce natural killer cells (NK cells) to become active and attack tumour cells. Scientists of Medigene Immunotherapies have developed new, fast and efficient methods for preparing autologous (patient-specific) mature dendritic cells which have relevant characteristics to activate both T cells and NK cells. The dendritic cells can be loaded with various tumour antigens to treat different types of cancer and are suited for treatment of minimal residual disease or use in combination therapies. Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on hematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit www.medigene.com . This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. Medigene ImmunotherapiesTM is a registered trademark of Medigene Immunotherapies GmbH. Trianta ImmunotherapiesTM is a registered trademark of Medigene Immunotherapies GmbH. These trademarks may be owned or licensed in select locations only. Contact Medigene Tel. : +49 - 89 - 20 00 33 - 33 01 Email: investor@medigene.com Press release as PDF This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Medigene AG via Globenewswire HUG#1899489

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Trianta Immunotherapies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Trianta Immunotherapies is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.